Welcome to our dedicated page for Mainz Biomed NV SEC filings (Ticker: MYNZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mainz Biomed N.V. (NASDAQ: MYNZ) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer, alongside AI‑generated explanations to help interpret them. Mainz Biomed is a molecular genetics diagnostic company specializing in early cancer detection, and its filings provide detail on capital raising activities, share capital structure, and periodic financial reporting.
Recent Form 6‑K reports describe key financing arrangements, such as a Securities Purchase Agreement for the sale of pre‑funded units that include pre‑funded warrants and ordinary warrants, and a Placement Agency Agreement with Maxim Group LLC. Another 6‑K outlines an Equity Distribution Agreement that allows the company to sell ordinary shares through at‑the‑market offerings on the Nasdaq Capital Market or other permitted venues, with information on commission rates, offering limits, and the role of the sales agent.
Filings also cover corporate governance and share capital changes. A Deed of Amendment to the Articles of Association, reported on Form 6‑K, details adjustments to the nominal value of ordinary and preferred shares, an increase in authorized share capital within specified limits, and the elimination of fractional shares. Additional 6‑K reports make available the Management’s Discussion and Analysis of Financial Condition and Results of Operations and unaudited financial statements for defined periods, along with associated Inline XBRL data.
On this page, users can access these documents as they are furnished to the U.S. Securities and Exchange Commission through EDGAR. AI‑powered summaries highlight the main points of lengthy filings, explain the implications of capital markets transactions, and point out where financial statements and management commentary can be found. Investors can also monitor how equity distribution programs, warrant offerings, and amendments to share capital may affect the company’s capital structure over time, all within a single, organized view of Mainz Biomed’s SEC reporting history.
Mainz Biomed N.V. filed a 424B5 prospectus supplement describing an at-the-market offering and summarizing key risks and capitalization. The company states it is an early-revenue stage business that has incurred operating losses since inception and may not reach profitability. Its commercial product ColoAlert is licensed and sold in Europe, while PancAlert remains an early-stage research candidate. The prospectus discloses potential dilution from outstanding instruments including up to 14,054,763 ordinary shares underlying warrants, 461,836 options, and 25,000 shares from convertible notes. It reports recent issuances of 1,321,000 ordinary shares since July 1, 2025 and net proceeds of approximately $2.6 million from sale of 2,222,222 pre-funded units, and contemplates sale of approximately $2.3 million of ordinary shares in this offering on a pro forma, as-adjusted basis. The filing lists numerous standard securities, regulatory, operational and market risks, and notes prior reverse-split activity to meet Nasdaq minimum bid-price requirements.
Mainz Biomed N.V. filed a Form 6-K as a foreign private issuer for the six months ended June 30, 2025. The company made available its Management’s Discussion and Analysis of Financial Condition and Results of Operations for this six-month period as Exhibit 99.1.
It also provided its unaudited financial statements as of, and for, the six months ended June 30, 2025 as Exhibit 99.2. These documents are incorporated by reference into Mainz Biomed’s existing shelf registration statement on Form F-3 and its equity compensation registration statement on Form S-8, allowing those offerings to rely on the updated interim financial and narrative information.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 723,092 ordinary shares of Mainz Biomed N.V., representing 9.99% of the class. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice exercises shared voting and dispositive power over 723,092 shares while neither Armistice nor Mr. Boyd claim sole voting or dispositive power. The Master Fund is identified as the party with the right to receive dividends or sale proceeds. The filing clarifies these holdings are reported to be held in the ordinary course of business and not for the purpose of changing control.
Transaction summary: On August 4, 2025, Mainz Biomed N.V. entered into a Securities Purchase Agreement to sell 2,222,222 pre-funded units, closing on August 5, 2025, for expected gross proceeds of approximately $3,000,000 before fees and expenses.
Each pre-funded unit consists of one pre-funded warrant (exercisable immediately at a remaining exercise price of $0.001) and one-and-one-half ordinary warrants (exercisable immediately at $1.35 per share, expiring five years from issuance). Ordinary warrants include anti-dilution protections for dividends, splits and similar transactions. Mainz paid the placement agent a fee equal to 7% of gross proceeds plus $85,000 in fixed fees. The SPA and related warrant forms were filed as exhibits to the Form F-1 and information is incorporated into the Form F-3 registration statement.